Stephen Spurgeon, MD
Dr. Spurgeon completed his undergraduate work at Bowdoin College and his medical school at Thomas Jefferson University. This was followed by his internal medicine residency, chief residency, and fellowship training at Oregon Health & Science University (OHSU) where he joined the faculty in 2009. Throughout his career, he has focused on the care of patients with lymphoma. He performs both clinical and translational research with a focus on novel therapeutics. He has held a number of leadership positions within the division of hematology and medical oncology and the Knight Cancer Institute (KC) at OHSU including c-chair of the clinical research review committee, the chief of hematologic malignancies section, and CLL research program. He currently is active within the SWOG lymphoma committee and serves as the Lymphoma Program Director for the Knight and in 2020 was named the Distinguished Scholar of Leukemia and Lymphoma Research, and endowed post at the KCI.
Financial relationships
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:GenentechTopic:ConsultingDate added:11/23/2022Date updated:12/15/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:JanssenTopic:ConsultingDate added:11/23/2022Date updated:12/15/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Astra ZenecaTopic:ConsultingDate added:11/23/2022Date updated:12/15/2023
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:BMS/CelgeneTopic:Clinical ResearchDate added:11/23/2022Date updated:12/15/2023
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:BeigeneTopic:Clinical ResearchDate added:11/23/2022Date updated:12/15/2023
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:AcertaTopic:Clinical REsearchDate added:11/23/2022Date updated:12/15/2023
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:MerckTopic:Clinical ResearchDate added:11/23/2022Date updated:12/15/2023
-
Attribution:OtherType of financial relationship:OtherIneligible company:SchrodingerTopic:Translational ResearchDate added:11/23/2022Date updated:12/15/2023